Bisantrene in advanced, hormone-resistant carcinoma of the prostate: an Illinois Cancer Council phase II study.
Vogelzang
N J
NJ
University of Chicago Hospitals, Illinois.
Lanzotti
V J
VJ
Muntean
B
B
Blough
R R
RR
D000368:Aged; D000369:Aged, 80 and over; D000873:Anthracenes / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D004341:Drug Evaluation; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality
D000873:Anthracenes; D000903:Antibiotics, Antineoplastic; C031404:bisantrene